Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of Excision Repair Cross Complementation Gene 1 (ERCC1) in Treatment Decision

NCT01188109 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT01188109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01188109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of Excision Repair Cross Complementation Gene 1 (ERCC1) in Treatment Decision
Lead sponsor
Emory University
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2010
Completion date
July 31, 2015
Enrollment
25 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer, pancreatic neoplasms